Contains the full prescribing information for the monoclonal antibody used in the treatment of non-Hodgkin's lymphoma.

Professor at the Univ. of North Carolina Medical School and survivor of non-Hodgkin's lymphoma presents tips for patients taking Rituxan.

Technical abstract on the antibody reports the results of clinical trials with details on side effects and cell recovery.

Medical news article discusses a conference paper about the remission rates on patients treated with the antibody. See the study results.

Reports on the antibody being cleared for marketing by the US Food and Drug Administration. Read about the patients' response rate in the trials.

Presents an overview of Rituxan and features links to articles and studies related to the genetically engineered antibody used in cancer therapy.

Treatment of some forms of relapsing non-Hodgkins Lymphoma is described here for professionals. Includes full prescribing information.

US Food and Drug Administration presents a letter outlining eight infusion related rituximab (Rituxan) events that ended in death.

Drug manufacturer, Genentech, provides an overview of the uses and chemical structure of this antibody therapy for non-Hodgkin's lymphoma.